ADPT President and COO Julie Rubinstein Sells $303K of Stock

Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation (ADPT), sold 11,881 shares valued at approximately $302,965 on October 13, 2026. The sale occurred at a price of $25.50 per share. This transaction was planned and adds to a series of recent insider movements at the company.

Inside Julie Rubinstein's Trade

Rubinstein's transaction adds to the recent trend where insiders have been active. The sale occurred at a time when Adaptive shares were trading at around $24.19. This price is below the company's 52-week high of $28.78, reflecting some downward pressure on the stock.

Other Institutional Activity in Adaptive Biotechnologies

Other institutional investors have also shown interest in Adaptive Biotechnologies. For instance, Wellington Management Group, LLP, increased its holdings by 2,054,031 shares, bringing its total to 5,911,366 shares valued at about $143.1 million. Blackrock Inc. added 1,835,856 shares to reach 15,139,159 shares worth approximately $366.5 million. Vanguard Capital Management LLC also increased its position by 309,576 shares, now holding 6,403,587 shares valued at around $155.0 million.

Adaptive Biotechnologies Corporation Stock Down 5.4%

As of the latest trading, Adaptive Biotechnologies shares are priced at about $24.19, having declined from a previous close of $28.61. This drop places the stock significantly below its recent highs, suggesting investors are weighing the company's growth potential against market conditions.

Recent Earnings

In its latest earnings report for the period ending June 30, 2026, Adaptive Biotechnologies reported revenue of $308.1 million, with a revenue growth of 21.5% year-over-year. The company faced a net margin of -20.7%, indicating challenges in profitability. Its next earnings call is scheduled for November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

In addition to Rubinstein's sale, Sharon Benzeno, the Chief Commercial Officer, sold 11,034 shares on June 26, 2026, valued at $231,714. Benzeno also made a significant purchase of 103,295 shares just a few days later on June 29, 2026, for around $751,605. Another insider, Susan Bobulsky, sold 5,000 shares on June 25, 2026, valued at approximately $102,500.

Analysts Set New Price Targets

On October 13, 2026, TD Cowen maintained a 'Buy' rating on Adaptive Biotechnologies with a price target of $32.00, up from $28.00. Morgan Stanley also maintained an 'Equal-Weight' rating with a target of $27.00, increased from $22.00. Meanwhile, Guggenheim kept a 'Buy' rating with a price target of $32.00, reflecting a positive outlook among some analysts despite recent volatility.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, headquartered in Seattle, WA, develops an immune medicine platform to diagnose and treat various diseases. The company uses immunosequencing to generate clinical data that helps decode the adaptive immune system, crucial for advancing personalized medicine.

Bottom Line

Investors should keep an eye on the upcoming earnings report on November 4, 2026, as market sentiment around Adaptive Biotechnologies continues to evolve. Recent insider sales and mixed analyst ratings suggest a complex outlook for the stock. Remember that this information is based on the latest filings and may not represent the current positions of those involved.